Variety of Antibody Responses to BNT162b2 and BBIBP-CorV Vaccinations Against COVID-19 Infections in Baghdad and Fallujah, Iraq


  • Mohammed A. Hamad Department of Biotechnology, College of Applied Science, University of Fallujah, Fallujah, Iraq
  • Mohammed N. Abed Department of Pathological Analysis, College of Applied Science, University of Fallujah, Fallujah, Iraq
  • Najemaddin A. Hamad Department of Religious Education and Islamic Studies, Sunni Endowment Office, Fallujah, Iraq
  • Mariam A. Abdul-Latif Department of Pathological Analysis, College of Applied Science, University of Fallujah, Fallujah, Iraq
  • Nehal A. Mohammed Department of Pathological Analysis, College of Applied Science, University of Fallujah, Fallujah, Iraq
  • Aya N. Abdul-Razaq Department of Pathological Analysis, College of Applied Science, University of Fallujah, Fallujah, Iraq
  • Rawaa A. Muhammed Fallujah Maternity and Children Hospital, Ministry of Health, Fallujah, Iraq



Antibody Responses, BNT162b2, BBIBP-CorV, COVID-19, IgG


The huge impact of COVID-19 worldwide led to the rapid development of vaccines with inadequate data about its longevity, effectivity, and safety. This study aims to evaluate the effectiveness and safety of COVID-19 vaccines available in Iraq and to measure longevity of created antibody response among different time points of both Pfizer-BioNTech and Sinopharm vaccines in Baghdad and Fallujah, Iraq.

A two-axis method was used: the first was cross sectional study on the vaccination state for COVID-19 in Baghdad and Fallujah, using an online survey contained questions about city, vaccine type, side effect, pre and post infections, and chronic diseases. The second part involved a prospective observational study of the vaccine’s immunological effectiveness and stability in 60 serum samples from completely vaccinated individuals (second dose) of Pfizer or Sinopharm along different time points (1 - 6 months) by measuring the SARS-CoV-2 Anti-RBD-IgG concentration and evaluating its correlation with pre-infection with COVID-19.

Among different types of vaccines available in Iraq, people in Baghdad and Fallujah preferred Pfizer vaccine over other available types, particularly those with chronic diseases. No statistically significant difference was noticed between IgG concentrations at different points of time, IgG concentrations in Pfizer vaccinated individuals were more elevated than Sinopharm, and all of Pfizer vaccinated people showed positive results. Our study established a synergistic impact between recent COVID-19 infection and vaccination, leading to increased levels of IgG antibodies, notably in individuals who received the Pfizer vaccine. Additionally, our findings demonstrate that IgG concentrations remained stable in vaccinated individuals even six months after completing the vaccination with second dose.


Download data is not yet available.


Almufty, H. B., Mohammed, S. A., Abdullah, A., and Merza, M. A. (2021). Potential adverse effects of COVID19 vaccines among Iraqi population; a comparison between the three available vaccines in Iraq; a retrospective cross-sectional study. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 15(5), 102207. DOI:
Andersen, A., Bjerregaard-Andersen, M., Rodrigues, A., Umbasse, P., and Fisker, A. B. (2017). Sex-differential effects of diphtheria-tetanus-pertussis vaccine for the outcome of paediatric admissions? A hospital based observational study from Guinea-Bissau. Vaccine, 35(50), 7018–7025. DOI:
Bulut, C. and Kato, Y. (2020). Epidemiology of COVID-19. Turkish journal of medical sciences, 50(SI-1), 563–570. DOI:
Buonfrate, D., Piubelli, C., Gobbi, F., Martini, D., Bertoli, G., Ursini, T., Moro, L., et al. (2021). Antibody response induced by the BNT162b2 mRNA COVID-19 vaccine in a cohort of health-care workers, with or without prior SARS-CoV-2 infection: a prospective study. Clinical Microbiology and Infection, 27(12), 1845–1850. DOI:
Centers for Disease Control and Prevention (2021). Duration of Isolation and Precautions for Adults with COVID-19. [Article]. Retrieved 13 December 2021 from URL:
Centers for Disease Control and Prevention (2022). Possible Side Effects After Getting a COVID-19 Vaccine. [Article]. Retrieved 12 January 2022 from URL:
Demonbreun, A. R., Sancillo, A., Vaught, L. A., Reiser, N. L., Pesce, L. L., McNally, E. M., and McDade, T. W. (2021). Antibody titers before and after booster doses of SARS-CoV-2 mRNA vaccines in healthy adults. medRxiv (Cold Spring Harbor Laboratory). DOI:
Ferenci, T. and Sarkadi, B. (2022). RBD-specific antibody responses after two doses of BBIBP-CorV (Sinopharm, Beijing CNBG) vaccine. BMC Infectious Diseases, 22(1). DOI:
Fischinger, S., Boudreau, C. M., Butler, A., Streeck, H., and Alter, G. (2019). Sex differences in vaccine-induced humoral immunity. Seminars in Immunopathology, 41(2), 239–249. DOI:
Grzelakowska, K., Kasprzak, M., and Kryś, J. (2021). COVID-19 and diabetes: a deadly duo? Medical Research Journal, 6(2), 119–124. DOI:
Gurbel, P. A., Wlodarczyk, Z., Stolarek, W., Wojtal, E., Buszko, K., Grzelakowska, K., Kosobucka-Ozdoba, A. et al. (2021). Determinants of the level of anti-SARSCoV- 2 IgG ANTibodiEs after vaccination (DANTE-SIRIO 7) study. A rationale and protocol of the study. Medical Research Journal, 6(4), 312–315. DOI:
Heyming, T. W., Nugent, D. J., Tongol, A., Knudsen-Robbins, C., Hoang, J., Schomberg, J., Bacon, K. et al. (2021). Rapid antibody testing for SARS-CoV-2 vaccine response in pediatric healthcare workers. International Journal of Infectious Diseases, 113, 1–6. DOI:
Kang, Y., Lim, J., Choe, K. W., Lee, K., Jo, D. H., Kim, M. S., Kim, J. M., and Kim, K. S. (2021). Reactogenicity after the first and second doses of BNT162b2 mRNA coronavirus disease vaccine: a single-center study. Clinical and Experimental Vaccine Research, 10(3), 282. DOI:
Lazarus, J. V., Ratzan, S. C., Palayew, A., Gostin, L. O., Larson, H. J., Rabin, K., Kimball, S. L., and El-Mohandes, A. (2021). A global survey of potential acceptance of a COVID-19 vaccine. Nature Medicine, 27(2), 225–228. DOI:
Marian, A. J. (2021). Current state of vaccine development and targeted therapies for COVID-19: impact of basic science discoveries. Cardiovascular Pathology, 50, 107278. DOI:
Mitchell, T. M. and Casella, C. R. (2017). No pain no gain? Adjuvant effects of alum and monophosphoryl lipid A in pertussis and HPV vaccines. Current Opinion in Immunology, 47, 17–25. DOI:
Polack, F. P., Thomas, S. H., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L. et al. (2020). Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. The New England Journal of Medicine, 383(27), 2603–2615. DOI:
Smith, B. A., Ricotta, E. E., Kwan, J. L., and Evans, N. G. (2022). COVID-19 risk perception and vaccine acceptance in individuals with chronic disease. medRxiv : the preprint server for health sciences, 2021.03.17.21253760. DOI:
Tsang, H. F., Chan, L., Cho, W. C., Yu, A. R., Yim, A. K., Chan, A., Ng, L. C., Wong, Y. P. et al. (2021). An update on COVID-19 pandemic: the epidemiology, pathogenesis, prevention and treatment strategies. Expert Review of Anti-infective Therapy, 19(7), 877–888. DOI:
Urakawa, R., Isomura, E. T., Matsunaga, K., Kubota, K., and Ike, M. (2022). Impact of age, sex and medical history on adverse reactions to the first and second dose of BNT162b2 mRNA COVID-19 vaccine in Japan: a cross-sectional study. BMC Infectious Diseases, 22(1). DOI:
Walsh, E. E., Frenck, R. W., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S. et al. (2020). Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. The New England Journal of Medicine, 383(25), 2439–2450. DOI:
World Health Organization (2021). Global Advisory Committee on Vaccine Safety (GACVS) review of latest evidence of rare adverse blood coagulation events with AstraZeneca COVID-19 Vaccine (Vaxzevria and Covishield). [Article]. Retrieved 01 August 2022 from URL:
World Health Organization (2022). COVID-19 advice for the public: Getting vaccinated. [Article]. Retrieved 01 May 2022 from URL:






Research Articles

How to Cite

Variety of Antibody Responses to BNT162b2 and BBIBP-CorV Vaccinations Against COVID-19 Infections in Baghdad and Fallujah, Iraq. (2023). UKH Journal of Science and Engineering, 7(1), 17-25.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>